sorafenib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 2459 284461-73-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY 43-9006
  • BAY 545-9085
  • BAY-545-9085
  • sorafenib tosilate
  • sorafenib
  • nexavar
  • sorafenib tosylate
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
  • Molecular weight: 464.83
  • Formula: C21H16ClF3N4O3
  • CLOGP: 5.46
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.43
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 12.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 39 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2005 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 2099.96 41.13 386 2321 3815 2351563
Hepatocellular carcinoma 1085.02 41.13 168 2539 464 2354914
Diarrhoea 935.43 41.13 380 2327 83184 2272194
Rash 781.65 41.13 305 2402 59253 2296125
Decreased appetite 548.25 41.13 195 2512 28696 2326682
Hypertension 523.94 41.13 186 2521 27175 2328203
Alopecia 495.74 41.13 169 2538 21832 2333546
Fatigue 445.65 41.13 230 2477 84643 2270735
Blister 440.40 41.13 118 2589 6653 2348725
Hepatic function abnormal 423.82 41.13 112 2595 5980 2349398
Hepatic cancer 400.91 41.13 74 2633 701 2354677
Off label use 349.57 41.13 187 2520 73411 2281967
Nausea 333.56 41.13 210 2497 111979 2243399
Hepatic encephalopathy 307.52 41.13 67 2640 1540 2353838
Pain in extremity 291.84 41.13 139 2568 42401 2312977
Stomatitis 287.53 41.13 92 2615 9618 2345760
Vomiting 284.52 41.13 162 2545 71440 2283938
Pyrexia 272.55 41.13 143 2564 53565 2301813
Weight decreased 264.72 41.13 115 2592 28256 2327122
Abdominal pain 262.27 41.13 121 2586 34253 2321125
Erythema 257.79 41.13 109 2598 25050 2330328
Skin exfoliation 252.87 41.13 74 2633 5716 2349662
Asthenia 252.36 41.13 130 2577 46796 2308582
Ascites 241.77 41.13 71 2636 5549 2349829
Blood pressure increased 240.77 41.13 93 2614 16893 2338485
Renal cell carcinoma 240.21 41.13 48 2659 709 2354669
Dry skin 200.66 41.13 64 2643 6588 2348790
Hyperkeratosis 189.99 41.13 40 2667 773 2354605
Death 183.52 41.13 129 2578 81339 2274039
Metastases to lung 175.02 41.13 43 2664 1688 2353690
Platelet count decreased 169.89 41.13 71 2636 15742 2339636
General physical health deterioration 160.35 41.13 66 2641 14073 2341305
Hepatic failure 160.30 41.13 52 2655 5637 2349741
Dyspnoea 159.54 41.13 117 2590 78616 2276762
Amylase increased 154.79 41.13 36 2671 1113 2354265
Constipation 154.69 41.13 73 2634 21556 2333822
Thyroid cancer 139.90 41.13 32 2675 917 2354461
Pruritus 131.87 41.13 83 2624 43257 2312121
Dehydration 131.55 41.13 66 2641 22229 2333149
Pain of skin 131.43 41.13 33 2674 1415 2353963
Malaise 129.31 41.13 90 2617 55495 2299883
Lipase increased 126.16 41.13 32 2675 1430 2353948
Abdominal pain upper 123.29 41.13 63 2644 22037 2333341
Pleural effusion 120.53 41.13 51 2656 11617 2343761
Anaemia 119.42 41.13 72 2635 34720 2320658
Glossodynia 112.46 41.13 31 2676 1914 2353464
Confusional state 109.17 41.13 60 2647 24284 2331094
Erythema multiforme 109.03 41.13 31 2676 2144 2353234
Liver disorder 100.92 41.13 38 2669 6376 2349002
Blood bilirubin increased 100.10 41.13 36 2671 5309 2350069
Oedema peripheral 99.50 41.13 56 2651 23707 2331671
Oral pain 99.48 41.13 32 2675 3365 2352013
Gait disturbance 96.75 41.13 54 2653 22491 2332887
Hypocalcaemia 95.28 41.13 32 2675 3851 2351527
Disease progression 93.13 41.13 48 2659 17047 2338331
Product use in unapproved indication 93.01 41.13 42 2665 11158 2344220
Gait inability 92.66 41.13 35 2672 5920 2349458
Metastatic renal cell carcinoma 91.49 41.13 18 2689 243 2355135
Dysphagia 90.69 41.13 43 2664 12762 2342616
Headache 88.40 41.13 84 2623 80095 2275283
Ammonia increased 87.64 41.13 21 2686 738 2354640
Hypophosphataemia 85.33 41.13 22 2685 1048 2354330
Aspartate aminotransferase increased 85.19 41.13 41 2666 12571 2342807
Dysphonia 83.34 41.13 33 2674 6331 2349047
Pain 80.16 41.13 71 2636 61786 2293592
Gastrointestinal haemorrhage 79.69 41.13 39 2668 12396 2342982
Hypokalaemia 79.19 41.13 37 2670 10617 2344761
Mucosal inflammation 78.72 41.13 30 2677 5194 2350184
Skin ulcer 78.47 41.13 28 2679 4031 2351347
Malignant neoplasm progression 77.61 41.13 38 2669 12090 2343288
Thrombocytopenia 74.42 41.13 43 2664 19088 2336290
Hospitalisation 73.14 41.13 39 2668 14814 2340564
Bone marrow failure 69.29 41.13 28 2679 5658 2349720
Pulmonary embolism 68.61 41.13 40 2667 18043 2337335
Chest pain 68.54 41.13 47 2660 28090 2327288
Skin lesion 67.49 41.13 25 2682 4000 2351378
Alanine aminotransferase increased 66.71 41.13 36 2671 13996 2341382
Dizziness 63.61 41.13 61 2646 58604 2296774
Metastases to bone 60.83 41.13 20 2687 2249 2353129
Epistaxis 60.63 41.13 30 2677 9749 2345629
Febrile neutropenia 57.59 41.13 30 2677 10852 2344526
Burning sensation 57.56 41.13 27 2680 7801 2347577
Alpha 1 foetoprotein increased 57.53 41.13 10 2697 64 2355314
Jaundice 56.54 41.13 24 2683 5484 2349894
Haemoglobin decreased 55.56 41.13 35 2672 18116 2337262
Cerebral infarction 54.56 41.13 22 2685 4415 2350963
C-reactive protein increased 53.60 41.13 24 2683 6231 2349147
Abdominal distension 53.09 41.13 28 2679 10383 2344995
Urinary tract infection 52.45 41.13 41 2666 29901 2325477
Skin toxicity 52.21 41.13 14 2693 776 2354602
Stevens-Johnson syndrome 51.97 41.13 21 2686 4238 2351140
Hyponatraemia 51.90 41.13 30 2677 13295 2342083
Back pain 50.43 41.13 41 2666 31618 2323760
Arthralgia 48.76 41.13 51 2656 54234 2301144
Rash macular 48.62 41.13 19 2688 3512 2351866
Pancreatic enzymes increased 46.30 41.13 10 2697 218 2355160
Pneumonia 45.49 41.13 47 2660 49249 2306129
Haemoptysis 45.13 41.13 18 2689 3509 2351869
Rash erythematous 45.12 41.13 21 2686 5955 2349423
Metastases to liver 44.68 41.13 17 2690 2924 2352454
Blood creatinine increased 44.46 41.13 25 2682 10508 2344870
Hypothyroidism 44.34 41.13 19 2688 4438 2350940
Rash papular 42.76 41.13 16 2691 2628 2352750
Oropharyngeal pain 42.38 41.13 25 2682 11493 2343885

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 4996.51 40.88 993 6558 2514 1736716
Hepatocellular carcinoma 4424.99 40.88 840 6711 1476 1737754
Diarrhoea 2502.96 40.88 1048 6503 52804 1686426
Hepatic cancer 1581.27 40.88 338 7213 1287 1737943
Decreased appetite 1545.85 40.88 595 6956 23276 1715954
Hepatic function abnormal 1515.76 40.88 436 7115 6638 1732592
Hypertension 1303.72 40.88 498 7053 18950 1720280
Ascites 1100.09 40.88 323 7228 5263 1733967
Fatigue 1041.32 40.88 569 6982 50212 1689018
Hepatic encephalopathy 1032.74 40.88 255 7296 2037 1737193
Rash 983.11 40.88 501 7050 38192 1701038
Hepatic failure 789.93 40.88 254 7297 5649 1733581
Alopecia 719.97 40.88 213 7338 3540 1735690
Renal cell carcinoma 694.82 40.88 171 7380 1337 1737893
Pyrexia 643.10 40.88 405 7146 45995 1693235
Asthenia 634.04 40.88 362 7189 34308 1704922
Dysphonia 592.03 40.88 181 7370 3374 1735856
Nausea 568.01 40.88 389 7162 50807 1688423
Weight decreased 549.43 40.88 286 7265 22467 1716763
Abdominal pain 547.31 40.88 280 7271 21210 1718020
Blister 534.11 40.88 173 7378 3919 1735311
Pain in extremity 456.30 40.88 236 7315 18236 1720994
Vomiting 418.45 40.88 289 7262 38026 1701204
Blood pressure increased 415.90 40.88 187 7364 10566 1728664
Platelet count decreased 410.44 40.88 212 7339 16311 1722919
Malaise 409.96 40.88 259 7292 29306 1709924
Metastases to lung 401.05 40.88 111 7440 1424 1737806
Death 386.88 40.88 390 7161 87053 1652177
Blood bilirubin increased 380.82 40.88 150 7401 6060 1733170
Off label use 361.03 40.88 265 7286 38306 1700924
Liver disorder 355.60 40.88 139 7412 5497 1733733
Stomatitis 354.14 40.88 137 7414 5267 1733963
Jaundice 345.78 40.88 139 7412 5923 1733307
General physical health deterioration 339.02 40.88 173 7378 12945 1726285
Amylase increased 338.37 40.88 93 7458 1159 1738071
Abdominal pain upper 331.29 40.88 161 7390 10840 1728390
Skin exfoliation 322.29 40.88 122 7429 4413 1734817
Dry skin 304.59 40.88 111 7440 3601 1735629
Dehydration 296.10 40.88 175 7376 17483 1721747
Erythema 281.60 40.88 157 7394 14031 1725199
Ammonia increased 275.67 40.88 73 7478 781 1738449
Anaemia 274.17 40.88 202 7349 29255 1709975
Dyspnoea 273.51 40.88 256 7295 51803 1687427
Constipation 273.45 40.88 157 7394 14843 1724387
Pruritus 261.61 40.88 179 7372 23043 1716187
Lipase increased 258.54 40.88 80 7471 1544 1737686
Confusional state 246.69 40.88 167 7384 21111 1718119
Alpha 1 foetoprotein increased 234.99 40.88 48 7503 134 1739096
Aspartate aminotransferase increased 224.16 40.88 123 7428 10633 1728597
Hyperkeratosis 212.36 40.88 56 7495 588 1738642
Hypophosphataemia 206.34 40.88 64 7487 1244 1737986
Abdominal distension 204.86 40.88 98 7453 6346 1732884
Epistaxis 201.14 40.88 105 7446 8201 1731029
Pleural effusion 196.16 40.88 114 7437 10996 1728234
Pain 191.52 40.88 157 7394 26500 1712730
Oedema peripheral 189.50 40.88 126 7425 15424 1723806
Thrombocytopenia 182.34 40.88 139 7412 21110 1718120
Metastatic renal cell carcinoma 181.86 40.88 49 7502 562 1738668
Metastases to bone 176.75 40.88 61 7490 1677 1737553
Liver carcinoma ruptured 175.59 40.88 32 7519 35 1739195
Gastrointestinal haemorrhage 167.52 40.88 113 7438 14154 1725076
Alanine aminotransferase increased 165.44 40.88 106 7445 12172 1727058
Oesophageal varices haemorrhage 161.40 40.88 44 7507 529 1738701
Dysphagia 160.26 40.88 97 7454 10071 1729159
Malignant neoplasm progression 158.76 40.88 109 7442 14049 1725181
Cough 156.79 40.88 122 7429 19075 1720155
Cerebral infarction 155.77 40.88 76 7475 5133 1734097
C-reactive protein increased 155.69 40.88 79 7472 5806 1733424
Gait inability 153.96 40.88 66 7485 3297 1735933
Encephalopathy 151.52 40.88 71 7480 4381 1734849
Pain of skin 149.90 40.88 43 7508 630 1738600
Erythema multiforme 146.02 40.88 53 7498 1693 1737537
Pneumonia 144.93 40.88 173 7378 46009 1693221
Renal failure 139.61 40.88 116 7435 19901 1719329
Melaena 137.98 40.88 70 7481 5140 1734090
Hospitalisation 128.85 40.88 92 7459 12608 1726622
Haematemesis 128.26 40.88 63 7488 4314 1734916
Haemoglobin decreased 127.32 40.88 103 7448 17011 1722219
Chest pain 125.72 40.88 109 7442 19805 1719425
Gastric ulcer 123.89 40.88 53 7498 2632 1736598
Gait disturbance 122.18 40.88 89 7462 12581 1726649
Disease progression 118.16 40.88 99 7452 17164 1722066
Skin fissures 111.56 40.88 35 7516 706 1738524
Metastases to lymph nodes 110.23 40.88 36 7515 830 1738400
Skin ulcer 109.06 40.88 49 7502 2739 1736491
Muscle spasms 108.34 40.88 80 7471 11541 1727689
Atrial fibrillation 108.26 40.88 89 7462 15022 1724208
Peripheral swelling 100.34 40.88 66 7485 7905 1731325
Tumour rupture 97.57 40.88 20 7531 57 1739173
Headache 96.65 40.88 122 7429 34254 1704976
Haemoptysis 96.57 40.88 54 7497 4822 1734408
Haematochezia 96.00 40.88 54 7497 4878 1734352
Hypoalbuminaemia 95.40 40.88 37 7514 1423 1737807
Product use in unapproved indication 94.92 40.88 68 7483 9354 1729876
Hypocalcaemia 94.16 40.88 46 7505 3110 1736120
Pulmonary embolism 93.69 40.88 77 7474 12982 1726248
Hypoglycaemia 92.19 40.88 64 7487 8374 1730856
White blood cell count decreased 91.14 40.88 76 7475 13073 1726157
Dizziness 90.38 40.88 118 7433 34243 1704987
Portal vein thrombosis 88.89 40.88 29 7522 666 1738564
Faeces discoloured 86.91 40.88 40 7511 2364 1736866
Dysgeusia 86.83 40.88 51 7500 4998 1734232
Metastases to central nervous system 86.43 40.88 35 7516 1510 1737720
Hyponatraemia 86.20 40.88 63 7488 8937 1730293
Mucosal inflammation 84.82 40.88 47 7504 4122 1735108
Liver abscess 83.42 40.88 27 7524 604 1738626
Interstitial lung disease 82.01 40.88 63 7488 9633 1729597
Hepatorenal syndrome 81.27 40.88 25 7526 471 1738759
Impaired healing 81.18 40.88 39 7512 2540 1736690
Hepatic cirrhosis 80.13 40.88 39 7512 2614 1736616
Blood sodium decreased 79.13 40.88 37 7514 2267 1736963
Pancreatic enzymes increased 77.79 40.88 20 7531 188 1739042
Insomnia 77.19 40.88 76 7475 16200 1723030
Arthralgia 76.86 40.88 90 7461 23354 1715876
Metastases to spine 74.69 40.88 22 7529 355 1738875
Proteinuria 74.63 40.88 38 7513 2806 1736424
Respiratory failure 73.03 40.88 70 7481 14435 1724795
Hyperammonaemia 72.85 40.88 28 7523 1050 1738180
Coma hepatic 72.70 40.88 18 7533 143 1739087
Cerebral haemorrhage 71.82 40.88 49 7502 6228 1733002
Blood albumin decreased 70.98 40.88 31 7520 1617 1737613
Back pain 70.41 40.88 73 7478 16540 1722690
Tumour haemorrhage 69.38 40.88 23 7528 556 1738674
Adverse drug reaction 68.93 40.88 43 7508 4695 1734535
Renal impairment 68.85 40.88 63 7488 12251 1726979
Gingival bleeding 67.85 40.88 28 7523 1268 1737962
Blood creatinine increased 67.75 40.88 66 7485 13880 1725350
Sepsis 67.68 40.88 77 7474 19361 1719869
Skin lesion 67.37 40.88 36 7515 2936 1736294
Hyperbilirubinaemia 67.21 40.88 33 7518 2254 1736976
Muscular weakness 66.39 40.88 57 7494 10192 1729038
Liver function test abnormal 66.23 40.88 45 7506 5681 1733549
Gamma-glutamyltransferase increased 66.05 40.88 43 7508 5055 1734175
Blood lactate dehydrogenase increased 65.49 40.88 38 7513 3637 1735593
Nephrotic syndrome 65.46 40.88 28 7523 1388 1737842
Glossodynia 64.63 40.88 23 7528 692 1738538
Altered state of consciousness 64.56 40.88 37 7514 3460 1735770
Hiccups 64.32 40.88 28 7523 1449 1737781
Hypothyroidism 63.68 40.88 33 7518 2527 1736703
Feeding disorder 63.52 40.88 24 7527 858 1738372
Cholangitis 63.30 40.88 26 7525 1163 1738067
Dry mouth 63.28 40.88 38 7513 3875 1735355
Cancer pain 62.83 40.88 19 7532 337 1738893
Loss of personal independence in daily activities 62.78 40.88 32 7519 2367 1736863
Hypophagia 61.89 40.88 36 7515 3461 1735769
Oropharyngeal pain 60.85 40.88 40 7511 4778 1734452
Jaundice cholestatic 60.38 40.88 23 7528 841 1738389
Infection 59.10 40.88 58 7493 12302 1726928
Oral pain 58.68 40.88 26 7525 1404 1737826
Tumour marker increased 58.63 40.88 15 7536 138 1739092
Eating disorder 58.48 40.88 25 7526 1237 1737993
Disseminated intravascular coagulation 58.19 40.88 35 7516 3579 1735651
Hypotension 57.35 40.88 88 7463 29566 1709664
Myocardial infarction 57.34 40.88 84 7467 27090 1712140
Renal cell carcinoma stage IV 56.07 40.88 11 7540 23 1739207
Varices oesophageal 55.93 40.88 20 7531 610 1738620
Abdominal discomfort 55.76 40.88 49 7502 9032 1730198
Gastrointestinal perforation 55.44 40.88 21 7530 756 1738474
Neoplasm progression 53.53 40.88 32 7519 3235 1735995
Bone marrow failure 53.41 40.88 38 7513 5162 1734068
Lymphopenia 52.85 40.88 27 7524 2006 1737224
Hepatic lesion 52.84 40.88 18 7533 474 1738756
Tumour thrombosis 52.51 40.88 11 7540 36 1739194
Acute kidney injury 51.82 40.88 92 7459 34852 1704378
Disorientation 51.69 40.88 38 7513 5431 1733799
Tumour lysis syndrome 50.65 40.88 25 7526 1726 1737504
Skin reaction 50.39 40.88 22 7529 1146 1738084
Protein induced by vitamin K absence or antagonist II increased 50.30 40.88 9 7542 8 1739222
Hyperamylasaemia 49.66 40.88 13 7538 132 1739098
Oedema 47.76 40.88 40 7511 6908 1732322
Duodenal ulcer 47.58 40.88 24 7527 1736 1737494
Cardiac failure 47.39 40.88 52 7499 12550 1726680
Seizure 47.22 40.88 66 7485 20375 1718855
Paraesthesia 46.18 40.88 47 7504 10404 1728826
Skin toxicity 45.68 40.88 17 7534 582 1738648
Mobility decreased 45.07 40.88 31 7520 3989 1735241
Aortic dissection 44.84 40.88 16 7535 485 1738745
Blood thyroid stimulating hormone increased 44.61 40.88 17 7534 622 1738608
Activated partial thromboplastin time prolonged 44.55 40.88 21 7530 1309 1737921
Hepatic cancer metastatic 44.01 40.88 12 7539 144 1739086
Skin discolouration 43.93 40.88 27 7524 2869 1736361
Haemobilia 43.82 40.88 11 7540 93 1739137
Fluid intake reduced 43.69 40.88 16 7535 523 1738707
Burning sensation 43.65 40.88 28 7523 3207 1736023
Hepatic enzyme increased 43.21 40.88 37 7514 6584 1732646
Hepatic rupture 43.07 40.88 9 7542 29 1739201
Rash macular 42.76 40.88 23 7528 1899 1737331
Electrolyte imbalance 42.40 40.88 21 7530 1460 1737770
Blood alkaline phosphatase increased 42.24 40.88 33 7518 5162 1734068
Thyroid cancer 42.05 40.88 14 7537 343 1738887
Therapy cessation 41.93 40.88 27 7524 3112 1736118
Multiple organ dysfunction syndrome 41.63 40.88 42 7509 9200 1730030
Metastases to adrenals 41.55 40.88 12 7539 180 1739050
Gastric antral vascular ectasia 41.49 40.88 10 7541 70 1739160
Transaminases increased 41.09 40.88 29 7522 3888 1735342

Pharmacologic Action:

SourceCodeDescription
ATC L01XE05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:48422 angiogenesis inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Carcinoma of thyroid indication 448216007
Renal cell carcinoma indication 702391001 DOID:4450
Hypophosphatemia contraindication 4996001
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Pancreatitis contraindication 75694006 DOID:4989
Angina pectoris contraindication 194828000
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic
pKa2 11.97 acidic
pKa3 12.61 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8124630 Jan. 12, 2020 TREATMENT OF CARCINOMA OF THE THYROID
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8841330 Jan. 12, 2020 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8618141 Feb. 11, 2023 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8877933 Dec. 24, 2027 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL Nov. 22, 2020 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Kd 8.13 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.51 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 10.68 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase INHIBITOR Ki 7.66 CHEMBL CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase INHIBITOR Ki 8.22 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 8.35 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.43 CHEMBL CHEMBL
Insulin receptor Kinase AGONIST IC50 5.28 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.21 CHEMBL
Myosin-IIIb Kinase Kd 5.15 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.93 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.54 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.74 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.12 CHEMBL
Aurora kinase A Kinase IC50 5.42 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 8.20 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.41 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.77 CHEMBL
Cyclin-dependent kinase-like 3 Kinase Kd 6.31 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.38 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.71 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 5.32 CHEMBL
Mitogen-activated protein kinase 15 Kinase Kd 7.34 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.64 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.11 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.16 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.36 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.02 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.46 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.70 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.47 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.14 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.27 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.55 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.07 CHEMBL
Aurora kinase C Kinase Kd 6.68 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.44 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.60 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.57 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.21 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 8.57 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.42 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.62 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.10 CHEMBL
Aurora kinase B Kinase Kd 6.36 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.25 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.89 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.27 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 5.52 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.44 CHEMBL
LIM domain kinase 1 Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.77 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.06 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.62 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 5.48 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme IC50 7.92 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 5.21 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.01 CHEMBL
Casein kinase I isoform alpha Kinase IC50 6.60 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.42 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.85 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.08 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.55 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.18 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.17 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.54 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.16 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.32 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase 13 Kinase Kd 5.18 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.70 CHEMBL
LIM domain kinase 2 Kinase Kd 5.02 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.02 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.15 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.21 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 6.60 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.19 CHEMBL
Mitogen-activated protein kinase 12 Kinase Kd 5.12 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.44 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.59 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase 3 Kinase IC50 7.74 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.96 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.12 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.96 CHEMBL
Cyclin-dependent kinase 8 Kinase Kd 6.51 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.89 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.89 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.44 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.41 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.38 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.59 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 6.65 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.66 CHEMBL
Purine nucleoside phosphorylase Unclassified IC50 7.90 CHEMBL
Platelet-derived growth factor receptor beta Unclassified INHIBITOR IC50 7.24 IUPHAR
Vascular endothelial growth factor receptor 3 Unclassified INHIBITOR IC50 7.70 IUPHAR

External reference:

IDSource
D000077157 MESH_DESCRIPTOR_UI
4025077 VUID
N0000175349 NUI
C1516119 UMLSCUI
D06272 KEGG_DRUG
5T62Q3B36J UNII
475207-59-1 SECONDARY_CAS_RN
420681006 SNOMEDCT_US
495881 RXNORM
20792 MMSL
422042001 SNOMEDCT_US
4025077 VANDF
d05691 MMSL
011160 NDDF
8234 INN_ID
CHEMBL1336 ChEMBL_ID
DB00398 DRUGBANK_ID
CHEMBL1200485 ChEMBL_ID
BAX PDB_CHEM_ID
CHEBI:50924 CHEBI
216239 PUBCHEM_CID
5711 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 18 sections